Updated:
Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd., a publicly traded biopharmaceutical firm, develops RNA-based therapeutics using its proprietary SemaPhore delivery platform.
Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda, with operational offices in Basel, Switzerland. The company originated from research into nanoparticle delivery systems for nucleic acids. Thomas Meyer serves as CEO and has led the firm through its transition from a hearing-loss therapeutic developer to a broader RNA delivery platform company. The firm’s strategy centers on its proprietary SemaPhore nanoparticle platform, which enables systemic delivery of siRNA and mRNA to target tissues. In 2023, Altamira announced a partnership with a European research institute to evaluate its platform in oncology (per a company press release, January 2023). The company has a pipeline including AM-125 (for acute vertigo), which achieved its primary endpoint in a Phase 2 trial, and preclinical programs in inner ear diseases. It also holds a collaboration with ReGenX Biosciences for lipid nanoparticle delivery (per SEC filings, 2022). Geographic focus is primarily the US and Europe. As of December 2023, the company reported approximately $2 million in cash and equivalents, with a market capitalization around $10 million. The team comprises roughly 15 full-time employees, per its 2023 annual report. Altamira maintains a subsidiary in the UK for regulatory affairs and has no disclosed family office or philanthropic arm. In early 2024, the company raised $5 million through a registered direct offering (per SEC filing, February 2024). A structural differentiator is its nano-platform’s ability to target the inner ear, a largely inaccessible therapeutic area, while repurposing the same delivery technology for other RNA indications. However, the company is publicly traded and operates under standard biotech governance, with no ties to family offices or notable private allocators.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Altamira Therapeutics?
Executive decisions are driven by CEO Thomas Meyer, who has led the company since its founding (per SEC filings). The board of directors oversees strategic direction, with no single principal family office controlling operations.
How does Altamira source proprietary deal flow?
The company’s pipeline stems primarily from internal R&D on its SemaPhore platform, supplemented by academic collaborations (per a 2023 press release). It does not operate as an investment firm or family office.
Is Altamira structured as a family office or a traditional biotech firm?
Altamira is a publicly traded company on the Nasdaq (ticker: ALT) and operates as a regular biotech entity. It has no family office structure or pooled investment vehicle.
What investment stages does Altamira typically target?
The firm does not make external investments. Its capital is deployed internally for clinical-stage drug development, with a focus on Phase 2 and later-stage trials for its lead candidates.
Which sectors does Altamira focus on?
Altamira focuses exclusively on RNA-based therapeutics, specifically in otology (hearing loss), neurology, and inflammatory diseases (per its website). It avoids non-biotech sectors entirely.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: